The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Subscribe To Our Newsletter & Stay Updated
